scholarly journals Assessing the Effect of Carcinoembryonic Antigen Tumor Marker Progression on Survival after Mastectomy in Patients With Breast Cancer: A Joint Survival Longitudinal Approach

2020 ◽  
Vol 9 (3) ◽  
pp. 111-115
Author(s):  
Amal Saki Malehi ◽  
Maedeh Raissizadeh ◽  
Shima Younespour ◽  
Mohammad Seghatoleslami ◽  
Mehran Hosseinzadeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Carcinoembryonic Antigen ◽  
Tumor Markers ◽  
Joint Modeling ◽  
Serum Tumor Markers ◽  
Significant Difference ◽  
Serum Cea ◽  
Southwest Of Iran ◽  
Over Time

Background: Breast cancer remains the most prevalent neoplasm in women, with more than 450000 deaths each year, worldwide. In cancer researches, several factors such as serum tumor markers have an important role in screening, treatment, and recurrence of the disease. Carcinoembryonic antigen (CEA) is one of the most widely used serum tumor markers in the clinical evaluation of patients with breast cancer. This study aimed to evaluate whether increasing serum CEA levels is an indicator of breast cancer patient’s survival or not. Materials and Methods: This retrospective study was done at Hematology Department of Shafa Hospital of Ahvaz, southwest of Iran. Only those patients who had mastectomy during 2006-2014 and regularly referred to the hospital were included. The joint survival longitudinal model was applied to analyze the data. JM package in R software was used for joint modeling analysis. Results: The five-year survival rate was 73.0%. Age and follow-up time were associated with CEA tumor marker values. Higher age is associated with higher CEA values over time (P=0.0156). There was a significant linear increasing trend in CEA values over time (P=0.0465). There was a significant difference between patients with and without nodal involvement (HR [95% CI]: 1.880 [1.330- 5.565]; P=0.0298). There was a positive correlation between CEA tumor marker levels and death (HR [95% CI]: 2.770 [1.369-5.603]; P=0.0046). Conclusion: Higher age is associated with higher CEA values over time. The involvement of lymph nodes increases the hazard of death. Death is more likely to occur in patients with higher CEA tumor marker levels.

Serum and Saliva Levels of Cancer Antigen 15-3, Carcinoembryonic Antigen, Estradiol, Vaspin, and Obestatin as Biomarkers for the Diagnosis of Breast Cancer in Postmenopausal Women

2020 ◽  
Vol 51 (6) ◽  
pp. 620-627
Author(s):  
Hyder Farahani ◽  
Jamal Amri ◽  
Mona Alaee ◽  
Fathollah Mohaghegh ◽  
Mohammad Rafiee
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Correlation Coefficients ◽  
Control Group ◽  
Case Group ◽  
Cancer Antigen ◽  
Healthy Women ◽  
Significant Difference ◽  
Serum Cea ◽  
Control Study

Abstract Objective To find suitable biomarkers for diagnosis of Breast cancer in serum and saliva; also, to examine the correlation between salivary and serum concentrations of suitable biomarkers. Methods This case-control study included 30 women with breast cancer as a case group and 30 healthy women as a matched control group. Blood and saliva specimens were collected from all participants. We evaluated serum and salivary cancer antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA), estradiol, vaspin, and obestatin concentrations. Mann-Whitney U testing and Spearman correlation coefficients were used for statistical analysis. Results Serum and salivary concentrations of estradiol were significantly higher in patients with breast cancer (BC) than in healthy women (P < .05). Also, serum CEA and salivary obestatin concentrations were significantly higher in BC patients than in the control group (P < .05). However, there was no significant difference between other parameters in patients with BC and controls. We observed a positive correlation between serum and salivary concentrations of CA15-3, as well as a negative correlation between serum and salivary concentrations of vaspin and obestatin. Conclusion The results of this study demonstrated that concentrations of CEA and estradiol in serum, obestatin in serum and saliva, and estradiol in saliva were significantly different between the 2 groups.

Serum Tumor Markers in Stage I-II Breast Cancer

2016 ◽  
Vol 12 (3) ◽  
pp. 285-289 ◽  
Author(s):  
Renato Tozzoli ◽  
Federica D';Aurizio ◽  
Flavio Falcomer ◽  
Stefano M.M. Basso ◽  
Franco Lumachi
Keyword(s):  
Breast Cancer ◽  
Tumor Markers ◽  
Stage I ◽  
Serum Tumor Markers

Reference Intervals for Serum Alpha-Fetoprotein and Carcinoembryonic Antigen in Chinese Han Ethnic Males from the Fangchenggang Area Male Health and Examination Survey

2011 ◽  
Vol 26 (1) ◽  
pp. 65-71 ◽  
Author(s):  
Xue Qin ◽  
Liwen Lin ◽  
Zengnan Mo ◽  
Hui Lv ◽  
Yong Gao ◽  
...  
Keyword(s):  
Carcinoembryonic Antigen ◽  
Reference Intervals ◽  
Alpha Fetoprotein ◽  
Male Health ◽  
Significant Difference ◽  
Reference Limits ◽  
Age Dependent ◽  
Serum Alpha Fetoprotein ◽  
Serum Cea ◽  
Normally Distributed

Objectives We calculated upper 95% reference limits for serum alpha-fetoprotein (AFP)and carcinoembryonic antigen (CEA) according to the CLSI/NCCLS C28-A3 guideline. Material and methods Serum samples from 1400 healthy male subjects were collected from the Fangchenggang Area Male Health and Examination Survey (FAMHES). Serum AFP and CEA values were measured by electrochemiluminescence immunoassay on COBAS 6000 system E601 (Elecsys module) immunoassay analyzers. Results Serum AFP and CEA values were not normally distributed but log normally distributed. The upper 95% reference limits of the reference intervals were ≤4.76 IU/mL (nonparametric) or ≤4.56 IU/mL (parametric) for AFP and ≤5.57 ng/mL (nonparametric) or ≤5.82 ng/mL (parametric) for CEA. The distribution of AFP levels was found to be consistent between the non-smoking and smoking (p=0.740) and non-drinking and drinking groups (p=0.698). The distribution of serum CEA levels was significantly higher in the smoking than the non-smoking group (p<105), whereas there was no significant difference in this respect between the non-drinking and drinking groups (p=0.147). A significant increase with age was found both for serum AFP and CEA levels, and the age-dependent reference intervals were calculated. Conclusions The reference intervals for serum AFP and CEA show a slight deviation compared to previously reported reference levels. Distinct reference intervals of serum CEA must be established for smoking and non-smoking populations. In addition, age-dependent reference intervals should be implemented in clinical laboratories.

scholarly journals The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

2019 ◽  
Vol 33 (5) ◽  
Author(s):  
Mingjian Lian ◽  
Cuixia Zhang ◽  
Dongdong Zhang ◽  
Ping Chen ◽  
Huijing Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Markers ◽  
Pathological Features ◽  
Serum Tumor Markers ◽  
Preoperative Serum

Carcinoembryonic antigen and interferon as tumor markers in breast cancer

1983 ◽  
Vol 22 (4) ◽  
pp. 254-256 ◽  
Author(s):  
Yoav Horn ◽  
Dalia Hacohen ◽  
Jacob L. Zeidman ◽  
Natalio Walach ◽  
Sally Sharf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Tumor Markers

Evaluating the impact of a trial in breast cancer tumor markers: A value of research analysis.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e16524-e16524
Author(s):  
Rahber Thariani ◽  
David K Blough ◽  
William Barlow ◽  
Norah Lynn Henry ◽  
Julie Gralow ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Clinical Trial ◽  
Tumor Marker ◽  
Tumor Markers ◽  
Societal Value ◽  
Cancer Tumor ◽  
The Impact

e16524 Background: Despite not being recommended by clinical guidelines, the tumor markers carcinoembryonic antigen (CEA), cancer antigen (CA)15-3, and CA 27.29 are used by some clinicians to screen for increased risk of breast cancer recurrence. Although additional research may be warranted to evaluate the benefits and risks of breast cancer tumor marker tests, clinical trials would likely need to involve thousands of women and would take many years to complete. We conducted an analysis to assess the societal value of a prospective randomized clinical trial (RCT) for breast tumor marker testing in routine follow-up of high-risk, stage II-III breast cancer survivors Methods: We used value of information techniques to assess the benefits of reducing uncertainty of using breast cancer tumor markers. We developed a decision-analytic model of biomarker testing in addition to standard surveillance at follow-up appointments every 3-6 months for five years. Expected value of sample information (EVSI) was assessed over a range of trial sizes and assumptions. Results: The overall value of research for an RCT involving 9,000 women was $166 million (EVSI). The value of improved information characterizing the survival impact of tumor markers was $81 million, quality-of-life $38 million, and test performance $95 million. Conclusions: Our analysis indicates that substantial societal value may be gained by conducting a clinical trial evaluating the use of breast cancer tumor markers. The most important aspects of the trial in our analysis were information gained on survival improvements as well as quality-of-life parameters associated with testing and test sensitivity and specificity. Our analysis indicates that smaller randomized trials, as well as adding quality of life instruments to existing trials, retrospective, and observational trials can also generate valuable and relevant information.

Serum CEA and CA 15-3 levels according to breast cancer subtypes.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11511-e11511 ◽  
Author(s):  
Isa Dede ◽  
Gungor Utkan ◽  
Hakan Akbulut ◽  
Yuksel Urun ◽  
Dilsa Mizrak ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Markers ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
Serum Levels ◽  
Carbohydrate Antigen ◽  
Breast Cancer Subtypes ◽  
Her2 Status ◽  
Cancer Subtypes ◽  
Serum Cea

e11511 Background: Carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 15-3 are frequently elevated in patients with metastatic breast cancer (MBC). In this study we aimed to correlate levels according to breast cancersubtypes with MBC. Methods: From January 2008 to December 2012, ninety-eight patients with MBC who were treated at Ankara University School Of Medicine, Department of Medical Onkology were included in this study.Serum levels of CEA and CA 15-3were measured and compared according to tumor estrogen receptor (ER), progesteron receptor (PR), and human epidermal growth factor receptor 2 (HER2) status. Results: In this cohort, overall ER,PR and HER2 positivity rates were 65 %,68%,and 58%, retrospectively. Positivite ER status was associated with elevated levels of CA 15-3 and cea. Of these, CA 15-3 levels elevated in 40.5% of ER positivite and 24.1 % of ER negativite patients (p=0.027). Similarly, 46.8 % of ER positivite and 18.2% of ER negativite patients had elevated levels of CEA (P=0.022). no association between PR and HER2 status and tumor markers was observed. Conclusions: The breast cancer subtypes are correlated with serum levels of tumor markers in patients with MBC. Tumor markers elevation may be associated with biological background of breast cancer subtypes. Further validation is needed to determine the role of these markers in diffrent tumor types for monitoring patients with MBC.

Sign in / Sign up

Export Citation Format

Share Document